InnovAge Revenue Beats, but EPS Misses and Stock Slips

InnovAge Holding (INNV) reported fiscal 2026 Q4 earnings on Sep 09th, 2026.

Revenue of $261.95 million beat analyst estimates of $238.28 million by 9.93%, driven by an 18.3% year-over-year increase. However, EPS of $0.06 missed the estimated $0.08 by 25%. The company maintained its fiscal 2027 guidance, projecting revenue between $1.05 billion and $1.085 billion and adjusted EBITDA of $105 million to $115 million, signaling confidence in disciplined margin management despite a tempered reimbursement environment.

Revenue

InnovAge Holding’s total revenue for fiscal 2026 Q4 rose 18.3% to $261.95 million, a notable improvement from the $221.42 million recorded in Q4 2025. This performance not only demonstrated strong operational momentum but also surpassed Wall Street consensus estimates, highlighting the company’s ability to drive top-line growth amidst a challenging healthcare landscape.

Earnings/Net Income

InnovAge Holding returned to profitability with an EPS of $0.06 in Q4 2026, reversing a loss of $0.01 per share in the prior year, marking a 1150.0% positive change. The company achieved a remarkable turnaround with net income of $9.78 million, a 295.3% swing from the $-5.01 million net loss in Q4 2025, setting a new record high for fiscal Q4 net income in six years. Despite beating revenue estimates, the EPS missed consensus targets by 25%, indicating that while profitability returned, per-share gains did not fully align with analyst expectations.

Price Action

The stock price of InnovAge Holding has dropped 5.73% during the latest trading day, has edged up 1.85% during the most recent full trading week, and has edged down 1.34% month-to-date.

Post-Earnings Price Action Review

Following the release of its fiscal 2026 fourth-quarter results, InnovAge Holding shares exhibited significant volatility, initially climbing 10.25% to $11.60 in after-hours trading as investors reacted positively to the revenue beat. The stock surged because revenue of $261.95 million exceeded analyst estimates of $238.28 million by nearly 10%, and the company demonstrated a sharp return to profitability with a net income of $9.78 million. However, this optimism was tempered by the fact that earnings per share of $0.06 missed the consensus estimate of $0.08 by 25%. Despite the EPS miss, the substantial improvement in adjusted EBITDA margin, which expanded to 9.3% from 5.1% a year earlier, underscored effective cost controls and operational efficiency. The initial post-earnings rally suggests that market participants prioritized the revenue surprise and margin expansion over the slight earnings per share shortfall, viewing the turnaround as a validation of the company’s strategic shift toward disciplined margin management.

CEO Commentary

Patrick Blair, Chief Executive Officer, InnovAge, characterized fiscal 2026 as an exceptional year marked by a 175% increase in adjusted EBITDA and a return to profitability despite one-time legal accruals. He outlined the transition to "InnovAge 3.0," focusing on scaling capabilities through technology, AI, and disciplined margin management rather than aggressive expansion. Strategic priorities include enhancing participant experience, optimizing clinical decision-making via AI pilots, and strengthening the core PACE business while maintaining strict compliance standards. Blair emphasized that growth will rely on execution, including census growth and cost control, rather than the robust rate increases seen previously. He expressed optimism about federal policy interest in PACE but maintained a cautious stance, stating that future outlooks do not assume regulatory changes. The tone reflects confidence in operational durability and long-term value creation.

Guidance

For fiscal 2027, InnovAge projects ending census between 8,625 and 8,850 participants, representing 5% to 7.5% growth. Total revenue is expected to range from $1.05 billion to $1.085 billion, with adjusted EBITDA targeted at $105 million to $115 million. De novo losses are anticipated to be minimal, between $0.4 million and $0.8 million. The company anticipates a net Medicare rate increase of 1.5% to 2.0% and low single-digit Medicaid increases, noting that the rate environment will be more tempered than in fiscal 2026. These projections reflect a focus on disciplined margin management and operational efficiency to sustain growth amidst a challenging reimbursement landscape.

Additional News

InnovAge Holding continues to navigate the senior healthcare sector with a focus on operational excellence and strategic growth. Recent discussions have highlighted the company's commitment to leveraging technology and artificial intelligence to enhance clinical decision-making and participant experiences within its PACE programs. Management has emphasized a shift towards "InnovAge 3.0," prioritizing disciplined margin management over aggressive expansion. This strategy aims to optimize existing capabilities and improve efficiency in a regulated environment. Additionally, the company remains attentive to potential federal policy changes regarding PACE reimbursement rates, maintaining a cautious outlook that does not rely on regulatory shifts for growth projections. Investors are monitoring these operational adjustments as key indicators of long-term value creation and sustainability in the face of a tempered reimbursement landscape.